BMY:US
$48.18
3.724%
Bristol-Myers Squibb CompanyNews & Events
Last updated: May 12, 2025, 4:41 PM ET
Improving Access to Care by Strengthening Local Health System Capacity
ACCESS Newswire MAY 7, 2025 9:45 AM EDTNORTHAMPTON, MA / ACCESS Newswire / May 7, 2025 / By Catharine Grimes , President of the Bris...READ ARTICLEBristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer
Business Wire MAY 6, 2025 6:59 AM EDTGallman’s Appointment is Effective Immediately Sandra Leung, Executive Vice Presid...READ ARTICLEBristol Myers Squibb Reports First Quarter Financial Results for 2025
Business Wire APR 24, 2025 6:59 AM EDTResults Reflect Continued Growth Portfolio Momentum and Disciplined Execution First qua...READ ARTICLEBristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy (xanomeline and trospium chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia
Business Wire APR 22, 2025 4:15 PM EDTCobenfy as an adjunctive treatment to atypical antipsychotics did not reach the threshold for a...READ ARTICLEU.S. Food and Drug Administration Updates CAMZYOS® (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications
Business Wire APR 17, 2025 8:21 PM EDTLabel updates include simplified twice-yearly echo monitoring for eligible CAMZYOS patients i...READ ARTICLEBristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial
Business Wire APR 14, 2025 4:15 PM EDTBristol Myers Squibb (NYSE: BMY) today announced the Phase 3 ODYSSEY-HCM trial evaluating Cam...READ ARTICLEU.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
Business Wire APR 11, 2025 3:49 PM EDTBased on the Phase 3 CheckMate-9DW trial, Opdivo plus Yervoy demonstrated a statistically...READ ARTICLEU.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer1
Business Wire APR 8, 2025 3:36 PM EDTBased on the Phase 3 CheckMate-8HW trial, Opdivo plus Yervoy demonstrated reduction in th...READ ARTICLEBristol Myers Squibb Receives Positive CHMP Opinion for Perioperative Regimen of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo for Resectable Non-Small Cell Lung Cancer in Patients with Tumor Cell PD-L1...
Business Wire MAR 28, 2025 8:53 AM EDTRecommendation based on Phase 3 CheckMate -77T trial showing significant event-free survival ...READ ARTICLEBristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications
Business Wire MAR 28, 2025 8:00 AM EDTRecommendation is based primarily on results from the Phase 3 CheckMate -67T trial which ...READ ARTICLE